AstraZeneca has chosen to close a study centre in the UK, consequently in a loss of up to 1,200 pharmaceutical jobs.
The business said it had shared with its employees additional information of proposals intended to advance the productivity of its global research and development organisation.
“The proposed changes, first outlined at the end of January, include focusing research efforts on a smaller number of disease areas and consolidating activities on to a reduced global footprint through the merger of some sites. Some of our sites will close,” stated the company.
The Loughborough site is anticipated to close by the end of 2011. A smaller facility in Cambridge is also to shut, the company said.
